Gilead Sciences, Inc.
GILD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $480,000 | $5,665,000 | $4,592,000 | $6,201,000 |
| Dep. & Amort. | $2,767,000 | $2,693,000 | $2,103,000 | $2,050,000 |
| Deferred Tax | -$1,844,000 | -$962,000 | -$1,552,000 | -$116,000 |
| Stock-Based Comp. | $835,000 | $766,000 | $644,000 | $635,000 |
| Change in WC | -$880,000 | -$2,303,000 | -$1,763,000 | $489,000 |
| Other Non-Cash | $9,470,000 | $2,147,000 | $5,048,000 | $2,125,000 |
| Operating Cash Flow | $10,828,000 | $8,006,000 | $9,072,000 | $11,384,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$523,000 | -$585,000 | -$728,000 | -$579,000 |
| Net Acquisitions | -$4,840,000 | -$1,152,000 | -$1,797,000 | -$1,584,000 |
| Inv. Purchases | -$736,000 | -$2,372,000 | -$1,942,000 | -$3,897,000 |
| Inv. Sales/Matur. | $2,592,000 | $1,844,000 | $2,002,000 | $2,910,000 |
| Other Inv. Act. | $58,000 | $0 | -$1,000 | $19,000 |
| Investing Cash Flow | -$3,449,000 | -$2,265,000 | -$2,466,000 | -$3,131,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $1,494,000 | -$270,000 | -$1,500,000 | -$4,750,000 |
| Stock Issued | $422,000 | $232,000 | $309,000 | $169,000 |
| Stock Repurch. | -$1,150,000 | -$1,000,000 | -$1,396,000 | -$546,000 |
| Dividends Paid | -$3,918,000 | -$3,809,000 | -$3,709,000 | -$3,605,000 |
| Other Fin. Act. | -$281,000 | -$278,000 | -$173,000 | -$145,000 |
| Financing Cash Flow | -$3,433,000 | -$5,125,000 | -$6,469,000 | -$8,877,000 |
| Forex Effect | -$40,000 | $57,000 | -$63,000 | -$35,000 |
| Net Chg. in Cash | $3,906,000 | $673,000 | $74,000 | -$659,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $6,085,000 | $5,412,000 | $5,338,000 | $5,997,000 |
| End Cash | $9,991,000 | $6,085,000 | $5,412,000 | $5,338,000 |
| Free Cash Flow | $10,305,000 | $7,421,000 | $8,344,000 | $10,805,000 |